摘要 |
The invention concerns quinazoline and quinoline derivatives of Formula (I) wherein Q<SUP>1 </SUP>includes a quinazoline or quinoline ring optionally substituted with a group such as halogeno, trifluoromethyl and cyano, or a group of the formula: Q<SUP>3</SUP>-X<SUP>1</SUP>- wherein X<SUP>1 </SUP>includes a direct bond and O and Q<SUP>3 </SUP>includes aryl, aryl-(1-6C)alkyl, heterocyclyl and heterocyclyl-(1-6C)alkyl; each of R<SUP>2</SUP>, R<SUP>3 </SUP>and R<SUP>5 </SUP>is hydrogen or (1-6C)alkyl, provides that one of the parts of groups R<SUP>2 </SUP>and R<SUP>4 </SUP>together, R<SUP>3 </SUP>and R<SUP>4 </SUP>together and R<SUP>5 </SUP>and R<SUP>4 </SUP>together forms a bond; R<SUP>6 </SUP>is an optionally substituted group selected from (2-6C) alkenyl, (2-6C) alkynyl, (3-7C)cycloalkyl and (3-7C) cycloalkenyl, or R<SUP>6 </SUP>is a substituted (1-6C) alkyl group; and Q<SUP>2 </SUP>includes aryl and aryl-(1-3C)alkyl or a pharmaceutically-acceptable salt thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the prevention or treatment of T cell mediated diseases or medical conditions in a warm-blooded animal.
|